bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

urlAlias

moreOnThisArticles

sponsorType

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Agence France-Presse

An anti-Covid drug widely used across the world may have caused mutations in the virus, researchers said, but there was no evidence that the changes had led to more dangerous variants.
Pharmaceutical giant Merck’s antiviral pill molnupiravir was one of the earliest treatments rolled out during the pandemic to prevent Covid becoming more severe in vulnerable people.
The drug, which is taken orally over a five-day course, works mainly by creating mutations in the virus with the goal of weakening and killing it.
However, a new UK-led study has shown that molnupiravir “can give rise to significantly mutated viruses which remain viable,” lead author Theo Sanderson said.
Sanderson, a geneticist at London’s Francis Crick Institute, emphasised that there is no evidence that “molnupiravir has to date created more transmissible or more virulent viruses”.
None of the variants that have swept the world were due to the drug, he added.
Terror of long Covid remains common even as pandemic eases, data shows
But “it is very difficult to predict whether molnupiravir treatment could potentially lead to a new widely circulating variant which people don’t have prior immunity to,” he added.
For the study, which was published in the journal Nature, the researchers sifted through databases of more than 15 million genome sequences of SARS-CoV-2, the virus that causes the Covid disease.
The researchers used this data to track changes in how the virus mutated during the pandemic, finding signs of a particular “mutational signature” in patients they believe is linked to molnupiravir.
In 2022, as the drug was prescribed in huge numbers, there was a significant increase in patients who had this mutational signature, the study found.
This signature was more commonly found in countries where the drug was widely prescribed, such as the United States, UK, Australia and Japan.
But in countries where it was not approved, including Canada and France, it was rarer.


Merck refuted the study, saying the researchers had relied on “circumstantial associations” between where and when the sequences were taken.
“The authors assume these mutations were associated with viral spread from molnupiravir-treated patients without documented evidence of that transmission,” Merck said in a statement.
Sanderson rebuffed this claim, saying the researchers had used “several independent lines of evidence to identify with confidence that molnupiravir drives this mutational signature”.
That included a separate analysis of treatment data in England, which found that more than 30 per cent of mutation events involving the signature were in people who had taken molnupiravir.
Maskless Biden laughs off pandemic guidance despite first lady having Covid
However, just 0.04 per cent of people in England were prescribed the drug in 2022, the study said.
Other anti-Covid drugs do not work in the same manner, so would not cause these kinds of mutations, Sanderson said.
Experts not involved in the study seemed to side with the British researchers.
Stephen Griffin, a virologist at the UK’s University of Leeds, said it was an “incredibly important, well-conducted piece of research”.

Jonathan Ball, a virologist at the University of Nottingham, said the research showed a “strong link” between molnupiravir and the occasional, limited spread of highly mutated genomes.
“What isn’t clear is if any of the transmitted viruses contained mutations which would change how they would behave – for example if they were more or less transmissible, more pathogenic or less susceptible to our immunity,” he added.
The experts emphasised that molnupiravir is not dangerous to people who are currently taking the drug.
Highly mutated Covid variant found but pandemic in ‘a different phase’
They also did not call for the drug to be abandoned altogether.
Molnupiravir is already being used by itself “less and less” as its effectiveness had waned against vaccinated people who are not at risk, Griffin said.
While the existing research might suggest that molnupiravir should no longer be prescribed by itself, “it shouldn’t be discarded and could still be valuable if we were to use it in drug combinations,” he added.
Sales of molnupiravir, sold under the brand name Lagevrio, topped US$20 billion last year. However sales fell 82 per cent in the second quarter of 2023 compared to the same period last year, according to Merck.
Additional reporting by Bloomberg


Hong Kong’s Peninsula Hotels sees ‘bleisure’ boom after pandemic curbs, CEO says

US could require US$15,000 bonds for some tourist, business visas

China’s Shenzhen, Guangzhou airports hit record highs, surpass pre-Covid passenger levels

Landmark US Chinatown survived Covid, anti-Asian violence – but tariffs pose new threat

Coronavirus pandemic

Anti-Covid drug molnupiravir may have led to virus mutations, study says

Pharmaceutical giant Merck’s antiviral pill molnupiravir was one of the earliest treatments rolled out during the pandemic. File photo: Shutterstock

Merck company disputed the idea that its drug was causing problematic new variants. File photo: Merck via AFP

Terror of long Covid remains common even as pandemic eases, data shows

Long Covid refers to a wide range of physical and mental health problems that persist four or more weeks after a coronavirus infection. Photo: Shutterstock

A Covid-19 vaccine is displayed at a medical centre in New York. Photo: Reuters

A sign reading, “Masks required in this area” is seen as travellers prepare to check in at the Miami International Airport in Florida in February 2021. Photo: Getty Images/TNS

Maskless Joe Biden laughs off pandemic guidance despite first lady having Covid

US President Joe Biden holds up a face mask while speaking at the White House on Wednesday. Photo: AFP

US President Joe Biden awards the Medal of Honour to retired US Army captain Larry Taylor at the White House on Tuesday. Photo: Reuters

Coronavirus: Highly mutated variant found in new countries but pandemic in ‘a different phase’

A nurse takes a swab sample at a drive-through coronavirus disease test site in El Paso, Texas, US in 2020. Photo: Reuters

Maria Van Kerkhove, Covid-19 technical lead at the World Health Organization. Photo: Reuters

Do I need to worry about Covid again, after the discovery of Eris, BA.2.86?

The WHO and US CDC are tracking a new, highly mutated lineage of the virus that causes Covid-19. Photo: Shutterstock

China’s rising Covid cases and new variant spark concerns about ‘third wave’

China no longer requires mass Covid-19 testing, which could make it harder for the government to closely monitor a “third wave” of infections, according to experts. Photo: Getty Images

News

World

Coronavirus

Health & Medicine

UK-led research raised concerns about accelerating the evolution of Covid-19
Drug maker Merck refuted that its treatment was likely to contribute to mutations


Pharmaceutical giant Merck’s antiviral pill molnupiravir was one of the earliest treatments rolled out during the pandemic to prevent Covid becoming more severe in vulnerable people.


Coronavirus pandemic: All stories

Disease

Medicine

Anti-Covid drug molnupiravir may have led to virus mutations, study says

.css-1mniedq{color:inherit;font-weight:inherit;font-size:inherit;font-family:inherit;line-height:inherit;}UK-led research raised concerns about accelerating the evolution of Covid-19 Drug maker Merck refuted that its treatment was likely to contribute to mutations

UK-led research raised concerns about accelerating the evolution of Covid-19

Drug maker Merck refuted that its treatment was likely to contribute to mutations